ArticlePeerJ2025
Dysregulated lipid metabolism in late preterm low birth weight neonates: A case-control study on maternal lipid levels and early metabolic programming implications.
Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: While low birth weight (LBW) is a recognized risk factor for adult metabolic syndrome, the unique lipid metabolic phenotype of late preterm low birth weight (LPTB-LBW) neonates-who experience dual exposures to shortened gestation and intrauterine growth restriction-remains uncharacterized. This study specifically examines whether the convergence of prematurity and growth restriction synergistically disrupts lipid metabolic programming. Methods: Using ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS), we compared lipidomic profiles of 88 plasma samples: 45 LPTB-LBW (34 Result: A total of 1,173 lipids were identified, categorized into five major lipid classes, with 349 significantly different lipids detected (324 upregulated and 25 downregulated) in the LPTB-LBW group. All glycerolipids were upregulated, accounting for 50% (162/324) of the upregulated lipids. Long-chain polyunsaturated triglycerides (TG) showed extreme elevations, such as TG (18:2_18:3_18:4) and TG (18:2_20:4_20:5). Monoglycerides, including MG (18:2) and MG (18:1), were also significantly elevated. Among glycerophospholipids (GP), 76 species were upregulated, with notable increases in phosphatidylethanolamines such as PE (O-18:0_22:3) and PE (18:2_22:1), while PG (20:4_22:6) was significantly reduced. All differentially expressed ceramides, including Cer (d26:3/33:1(2OH)), Cer (d29:2/30:2(2OH)), and Cer (d28:3/31:1(2OH)), were upregulated, whereas sphingosines were downregulated. Cholesterol esters were decreased, while bile acids, free fatty acids and acylcarnitines were elevated. KEGG pathway enrichment analysis highlighted significant perturbations in cholesterol, glycerolipid, and sphingolipid metabolism. Maternal high-density lipoprotein cholesterol (HDLC) levels during early pregnancy showed exclusive negative correlations with neonatal lipids, particularly triacylglycerol TG (16:0_18:2_18:2) ( Conclusions: LPTB-LBW neonates exhibit a unique lipidomic phenotype marked by hyperaccumulation of glycerolipids (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.